Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis (Q34185599)

31 July 2017

title

Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis (English)

1 reference

31 July 2017

0 references

Kelly A Rouster-Stevens

1

1 reference

31 July 2017

Gabrielle A Morgan

2

1 reference

31 July 2017

Deli Wang

3

1 reference

31 July 2017

Lauren M Pachman

4

1 reference

31 July 2017

publication date

1 October 2010

1 reference

Arthritis Care and Research

31 July 2017

published in

1 reference

31 July 2017

volume

62

1 reference

31 July 2017

issue

10

1 reference

31 July 2017

page(s)

1446-1451

1 reference

Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

The treatment and prognosis of dermatomyositis: an updated review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Does mycophenolate mofetil increase the incidence of infections in stable renal transplant recipients initially treated with a two-drug regimen?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Mycophenolate mofetil and its mechanisms of action

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Polymyositis and dermatomyositis (first of two parts)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Safety and tolerance of sodium mycophenolate in patients after renal transplantation--an observational study.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Mycophenolate mofetil treatment in resistant myositis.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Duration of illness is an important variable for untreated children with juvenile dermatomyositis

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2952049

Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases

28 October 2018

1 reference

12 December 2020

Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence

1 reference

12 December 2020

Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies

1 reference

12 December 2020

Dermatomyositis (systemic angiopathy) of childhood

1 reference

12 December 2020

Opportunistic infections in polymyositis and dermatomyositis

1 reference

12 December 2020

Mycophenolate mofetil in dermatomyositis: is it safe?

1 reference

12 December 2020

RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis

1 reference

12 December 2020

Treatment of the inflammatory myopathies: update and practical recommendations

1 reference

12 December 2020

Identifiers

DOI

10.1002/ACR.20269

1 reference

31 July 2017

1 reference

31 July 2017

1 reference